SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles
- TEL AVIV, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), announced that AutoMax Motors Ltd., (“AutoMax”), a leading automotive importer and distributor in Israel with which the Company has entered into an agreement and plan of merger, received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group Co., Ltd. (“JAC Motors”), a globally recognized Chinese automotive company. This marks a significant milestone in AutoMax's direct import and distribution operations, launched under agreements signed earlier this year with JAC Motors.
- 01/13/2025
|
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results
- TEL AVIV, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that MitoCareX Bio Ltd. (“MitoCareX”), its joint venture with Dr. Alon Silberman, is expanding its research and development efforts into pancreatic cancer following encouraging initial in-vitro results.
- 01/07/2025
|
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?
- On Monday, SciSparc Ltd SPRC stock is trading higher with a session volume of 30.86 million compared to an average volume of 7.73 million as per data from Benzinga Pro.
- 01/06/2025
|
SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
- TEL AVIV, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY0), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, the publication of a European patent application submitted by Clearmind under the European Patent Office for innovative combination therapy of MEAI and N-Acylethanolamines, to binge behavior including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.
- 01/06/2025
|
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder
- TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the renewal of its approval from the Israeli Medical Cannabis Agency ("IMCA") at the Israeli Ministry of Health to conduct its clinical trial for SCI-210 in children with autism spectrum disorder ("ASD"). SCI-210 is a proprietary combination of cannabidiol (“CBD”) and CannAmide™.
- 12/31/2024
|
S&P 500 Edges Lower, SciSparc Shares Surge
- U.S. stocks traded slightly lower toward the end of trading, with the S&P 500 edging lower on Thursday.
- 12/26/2024
|
SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation
- TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), announced that AutoMax Motors Ltd., (“AutoMax”), a leading automotive importer and distributor in Israel with which the Company has entered into an agreement and plan of merger, received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group Co., Ltd. (“JAC Motors”), a globally recognized Chinese automotive company. This marks a significant milestone in AutoMax's direct import and distribution operations, launched under agreements signed earlier this year with JAC Motors.
- 12/26/2024
|
SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company
- According to the LOI , SciSparc's pharmaceuticals assets are valued at approximately US $11. 6 million
- 12/16/2024
|
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
- FDA confirm s that SciSparc's study may proceed only a month after application submission
- 09/30/2024
|
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
- The intended selling valuation represents an increase of 47 % from the valuation at the time of SciSparc's initial investment in MitoCareX Bio
- 09/26/2024
|
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
- FDA confirm s that SciSparc's study may proceed following the application submission a month ago
- 09/23/2024
|
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
- Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel will take part in the trial
- 09/18/2024
|
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
- This innovative drug combination treatment focuses on boosting safety and efficacy in mental health and addiction care TEL AVIV, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd.
- 09/16/2024
|
SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer
- To date, SciSparc has advanced $4.25 million to Automax under the Bridge Loan agreement and amendments thereto
- 09/11/2024
|
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
- Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments TEL AVIV, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd.
- 09/06/2024
|
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
- TEL AVIV, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has announced the publication of its patent application under the international Patent Cooperation Treaty, for innovative combinations of ketamine and N-acylethanolamines.
- 08/29/2024
|
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
- SciSparc would be entitled to receive consideration valued at $3 million in Polyrizon securities, as well as potential milestone fees of approximately $3 million in cash
- 08/28/2024
|
SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
- SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel
- 08/23/2024
|
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
- Professor Peled is the Director of the Oncology Department at the Shaare Zedek Medical Center , Jerusalem , Israel, and the head of the Global Multidisciplinary Practice Standards Committee (GMPSC) of the IASLC
- 08/22/2024
|
SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
- The clinical trial for SCI-210 is conducted in Israel, after which the Company aims to move forward with the commercialization process of SCI-210, first in the Israeli market
- 08/19/2024
|
Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy
- Friday, SciSparc Ltd. SPRC signed an exclusive patent license agreement with Polyrizon Ltd to out-license its SCI-160 program to treat pain.
- 08/19/2024
|
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
- SciSparc will receive consideration in shares, and in addition may receive cash payments and fees if certain development milestones are met
- 08/16/2024
|
Why Is SciSparc (SPRC) Stock Up 94% Today?
- SciSparc (NASDAQ: SPRC ) stock is on the rise Thursday after the clinical-stage pharmaceutical company provided investors with an update concerning its AutoMax Motors merger. The big news here is The Jerusalem District Court in Israel approving AutoMax's petition to convene special class meetings of shareholders to approve the SciSparc merger.
- 08/15/2024
|
SciSparc Updates Regarding the Status of the AutoMax Merger
- SciSparc provides investors with an update regarding the status of the merger agreement with AutoMax, including the court's approval of AutoMax's petition to convene special class meetings of its shareholders to approve the Merger with the Company
- 08/14/2024
|
SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
- SciSparc has been collaborating with Clearmind Medicine to create effective treatments for obesity and metabolic syndrome by combining SciSparc's Palmitoylethanolamide (PEA) with Clearmind's MEAI
- 08/06/2024
|
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
- The discovery was demonstrated by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors
- 07/22/2024
|
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
- SciSparc will receive additional payments and execution fees if certain milestones are met
- 07/17/2024
|
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
- TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system (the “Company” or “SciSparc”), today announced it has received a written notice (the “Notice”) from Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement. The Notice has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares, and during the grace period, as may be extended, the Company's ordinary shares will continue to trade on Nasdaq under the symbol “SPRC”.
- 07/16/2024
|
Why Is SciSparc (SPRC) Stock Up 25% Today?
- SciSparc (NASDAQ: SPRC ) stock is up on Tuesday after the clinical-stage pharmaceutical company announced a new patent application covering its weight loss treatment. SciSparc notes that this patent covers the company's collaboration with Clearmind Medicine (NASDAQ: CMND ).
- 07/16/2024
|
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
- TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that an additional patent application with the United States Patent and Trademark Office (“USPTO”) was submitted as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems and invented with Professor Joseph Tam from the Hebrew University's technology transfer company, Yissum. The patent application is for the novel proprietary composition of Palmitoylethanolamide (“PEA”), the active ingredient of SciSparc's proprietary CannAmide™ with Clearmind's innovative MEAI compound (5-methoxy-2-aminoindane) for treating metabolic syndrome and obesity.
- 07/16/2024
|
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
- According to the agreement, SciSparc's pharmaceuticals assets are valued at approximately $11.6 million TEL AVIV, Israel, July 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today it signed a non-binding letter of intent (the “LOI”) to spin off its advanced clinical stage pharmaceutical portfolio and its equity stake in SciSparc Nutraceuticals Inc. (collectively, the “Target Assets”).
- 07/08/2024
|
SciSparc Secures Strategic Advantage with Grant of European Patent
- TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that the European Patent Office granted the Company's patent application titled “Compositions and Methods of Potentiating Antimicrobials”. This is in addition to the patent titled “Compositions and Methods of Potentiating Antimicrobials” previously granted by the United States Patent and Trademark Office. This patent grant bolsters the Company's intellectual property portfolio, extending the protection of its global patent holdings.
- 05/31/2024
|
Action Alliance Research: Family, Friends Need More Resources and Support to Help Loved Ones Who Are Struggling with Their Mental Health
- WASHINGTON--(BUSINESS WIRE)--New research provides resources for increasing 988 usage and access among populations disproportionately impacted by suicide and their loved ones.
- 05/21/2024
|
SciSparc to Acquire AutoMax
- TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it signed a merger agreement (the “Agreement”) with AutoMax Motors Ltd. (“AutoMax”), a leading vehicle importer company in Israel.
- 04/11/2024
|
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
- TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has submitted a patent application under the international Patent Cooperation Treaty.
- 03/27/2024
|
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
- MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that MitoCareX Bio Ltd.
- 03/21/2024
|
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
- TEL AVIV, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that it has been granted a patent for its core-technology, the combination of cannabinoids and n-acylethanolamines, by the Canadian Intellectual Property Office (the “Patent”). The Patent aligns seamlessly with the Company's proprietary technology and is designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits.
- 03/18/2024
|
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
- First patient has been dosed in the randomized, controlled, double blind clinical trial for Autism Spectrum Disorder in pediatric patients
- 03/14/2024
|
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
- MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March 12, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that MitoCareX Bio Ltd.
- 03/12/2024
|
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
- TEL AVIV, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that the first patient has been enrolled in the Company's clinical trial assessing the efficacy and safety of SCI-210 for the treatment of children with autism spectrum disorder (“ASD”) between the ages of 5 and 18.
- 03/08/2024
|
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
- The Company's most recent patent further solidifies its position, complementing existing grants in the U.S., Japan, Australia and other key jurisdictions
- 03/07/2024
|
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
- TEL AVIV, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today its had been received patent approval for its proprietary combination of opioids and n-acylethanolamines for pain treatment (the “Patent”).
- 03/06/2024
|
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
- The SCI- 210 treatment is now available at clinical site for autism spectrum disorder clinical trial in pediatric patients, in accordance with enrollment initiat ion
- 02/29/2024
|
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
- TEL AVIV, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind filed three patent applications under the international Patent Cooperation Treaty (“PCT”).
- 02/27/2024
|
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
- TEL AVIV, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind filed three patent applications under the international Patent Cooperation Treaty.
- 02/20/2024
|
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
- The clinical trial for SCI-210 will be conducted in Israel, after which the company aims to move forward with the commercialization process of SCI-210 first in the Israeli market
- 01/29/2024
|
Why Is SciSparc (SPRC) Stock Up 50% Today?
- Cannabinoid biotech specialist SciSparc (NASDAQ: SPRC ) is enjoying a much-needed boost on Wednesday thanks to a key investment deal. This morning, management announced an equity purchase agreement with a private-equity fund, reflecting confidence in the otherwise embattled business.
- 01/24/2024
|
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
- TEL AVIV, Israel, Jan. 24, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that it has entered into a standby equity purchase agreement (the “SEPA”) with YA II PN, Ltd. (“YA”), a fund managed by Yorkville Advisors Global, LP. Under the terms of SEPA, YA is committed to purchase up to $20 million of the Company's ordinary shares over the next thirty-six-month period, subject to a beneficial ownership cap of 4.99% of the share capital of the Company. The purchase price of the ordinary shares will be at a 3% discount of the weighted average price of the Company's ordinary shares during the three consecutive trading day period commencing on the trading day of the delivery of an advance notice by the Company.
- 01/24/2024
|
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
- TEL AVIV, Israel, Jan. 19, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it entered, as lender, into a bridge loan agreement (the "Agreement) with a leading vehicle importer company in Israel, as borrower (the "Target Company"), pursuant to which the Target Company received a bridge loan (the “Bridge Loan”) in the amount of $1.4 million, further to the previously-announced non-binding letter of intent (the “LOI”) for the Company to acquire the Target Company (the “Acquisition”).
- 01/19/2024
|
SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
- The collaboration included six different provisional patent applications filed by Clearmind with the United States Patent and Trademark Office in February 2023 to protect the novel combinations of psychedelics with SciSparc's PEA
- 01/04/2024
|
Why Is SciSparc (SPRC) Stock Up 25% Today?
- Shares of drug discovery specialist SciSparc (NASDAQ: SPRC ) are popping sharply today on encouraging clinical study results. Specifically, the company's joint venture (JV) project MitoCareX Bio achieved positive results regarding small-molecule screening processes.
- 12/13/2023
|
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
- MitoCareX Bio met its second milestone as part of its joint venture agreement with the Company TEL AVIV, Israel, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, previously announced that MitoCareX Bio Ltd.
- 12/13/2023
|
SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel
- TEL AVIV, Israel, Dec. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today updates regarding the negotiation following the signing of a non-binding letter of intent ("LOI") with a leading vehicle importer company in Israel (the "Target Company"), on November 22, 2023. According to the new negotiated terms, the Company will acquire 100% of the Target Company and will establish a new wholly-owned Israeli subsidiary, which would in turn merge with and into the Target Company (the “Acquisition”). Following the Acquisition, it is contemplated that SciSparc shareholders will hold approximately 50.01% of the share capital of the post-closing combined company (the “Combined Company”), compared to 20%, as reflected in the previous announcement.
- 12/07/2023
|
SciSparc's stock stays hot after biopharmaceutical company sets merger deal
- SciSparc Ltd.'s stock SPRC was up 74% on Friday, two days after the clinical-stage biopharmaceutical company said it agreed to merge with an unnamed company in Israel.
- 11/24/2023
|
Why Is SciSparc (SPRC) Stock Up 20% Today?
- SciSparc (NASDAQ: SPRC ) stock is rising higher on Wednesday as investors react to the company signing a letter of intent for a merger. That merger would be with a leading vehicle importer company in Israel that goes unnamed in the SciSparc press release.
- 11/22/2023
|
Why Is SciSparc (SPRC) Stock Up 47% Today?
- SciSparc (NASDAQ: SPRC ) stock is taking off on Wednesday after the company released results from a Phase IIa trial of SCI-110 as an Alzheimer's Disease agitation treatment. The clinical trial covered 18 patients with Alzheimer's who have been dealing with agitation symptoms.
- 11/15/2023
|
Why Is SciSparc (SPRC) Stock Up 58% Today?
- SciSparc (NASDAQ: SPRC ) stock is taking off on Tuesday after the pharmaceutical company posted positive patent news. The big news here is the company's patent for ‘Combination of Opioids and N-Acylethanolamines for pain treatment” getting approval from IP Australia.
- 10/31/2023
|
Why Is SciSparc (SPRC) Stock Up 105% Today?
- SciSparc (NASDAQ: SPRC ) stock is rising higher on Tuesday after the pharmaceutical company regained listing compliance. SciSparc notes that the Nasdaq Exchange has closed a complaint against the company concerning the price of its shares.
- 10/17/2023
|
The 7 Most Promising Penny Stocks to Buy in June
- Some of the most promising penny stocks are up-and-coming and just just getting started. The world of penny stocks is all about speculating which young firms have the potential to become the next big companies.
- 06/07/2023
|
Hot Penny Stocks To Watch After UCAR Stock Explodes
- If there's one thing we know now it's that catalysts play a significant role in trading penny stocks. This is where things like sympathy sentiment can play a much larger role.
- 06/01/2023
|
The Role of Fundamental Analysis in Penny Stock Investing
- How fundamental analysis helps investing in penny stocks The post The Role of Fundamental Analysis in Penny Stock Investing appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 02/19/2023
|
Why Is SciSparc (SPRC) Stock Up 14% Today?
- SciSparc (NASDAQ: SPRC ) stock is taking off on Friday as investors react to an update on its drug development joint venture. MitoCareX Bio is the joint venture behind today's rise.
- 02/17/2023
|
5 Penny Stocks To Watch After Big News This Week
- Penny stocks to watch with news that are turning heads in the stock market this week. The post 5 Penny Stocks To Watch After Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/17/2023
|
Buying Penny Stocks? 3 Analyst Recommendations to Use
- Check these recommendations for buying penny stocks The post Buying Penny Stocks? 3 Analyst Recommendations to Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/31/2022
|
Buying Penny Stocks This Week? What You Need to Know
- Which penny stocks are you watching right now? The post Buying Penny Stocks This Week?
- 10/03/2022
|
Top Penny Stocks to Buy Right Now? 3 for Your Mid-September List
- Looking for penny stocks to buy today? 3 for your watchlist right now The post Top Penny Stocks to Buy Right Now?
- 09/15/2022
|
Why Is SciSparc (SPRC) Stock Up 50% Today?
- Source: Shutterstock Who lit the fuse sending SciSparc (NASDAQ: SPRC ) stock to the skies this morning? As of this writing, SPRC stock is surging 50% on news that the company is preparing to acquire natural supplements company Wellution, a top seller of certain product types on Amazon (NASDAQ: AMZN ).
- 09/14/2022
|
Why Are Psychedelics Stocks Up Today?
- Psychedelics stocks, like Seelos Therapeutics (NASDAQ: SEEL ), Scisparc (NASDAQ: SPRC ) and Bright Minds Biosciences (NASDAQ: DRUG ), are taking off today. This morning, it was announced that the Michael J.
- 08/24/2022
|
Best Penny Stocks to Watch as the Market Turns Bullish Today
- Which penny stocks are you watching today? The post Best Penny Stocks to Watch as the Market Turns Bullish Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/26/2022
|
3 Penny Stocks Worth Watching This Week
- Are these penny stocks on your list right now? The post 3 Penny Stocks Worth Watching This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/24/2022
|
12 Stocks Halted On A Circuit Breaker This Week
- A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore, and bring order to the markets.
- 03/25/2022
|
